Tag: <span>ak care</span>

Home / ak care
Post

Health Canada is updating the labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccines

Health Canada is informing Canadians and healthcare professionals about changes to the product labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccines.The Department is updating the label of the Janssen COVID-19 Vaccine to provide additional information about the very rare risk of immune thrombocytopenia (ITP), an autoimmune condition, and the rare risk of venous thromboembolism...

Post

Reports to poison centres concerning ivermectin as a prevention or treatment for COVID-19 have increased over the summer months

Health Canada is reminding Canadians not to use ivermectin to prevent or treat COVID-19. Canadian poison centres have seen an increase in reports concerning ivermectin over the summer. There is no evidence that ivermectin works to prevent or treat COVID-19, and it is not authorized for this use. To date, Health Canada has not received...

Post

Ivermectin not authorized to prevent or treat COVID-19; It may cause serious health problems

Health Canada has received concerning reports of the use of veterinary ivermectin to prevent or treat COVID-19. Canadians should never consume health products intended for animals because of the potential serious health dangers posed by them. In this light, Health Canada is advising Canadians not to use either the veterinary or human drug versions of...

Post

Vaccines for COVID-19

https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19/vaccines.html?utm_source=sfmc&utm_medium=email&utm_campaign=OMA+News+August+13+2021&utm_term=https%3a%2f%2fwww.canada.ca%2fen%2fpublic-health%2fservices%2fdiseases%2fcoronavirus-disease-covid-19%2fvaccines.html&utm_id=145621&sfmc_id=7580034 HMC

Post

Legionellosis increasing in Ontario

Reports of Legionellosis have been increasing throughout Ontario. There have been 13 confirmed and 1 probable cases of legionellosis reported between July 1 and July 28, 2021 in the Region of Peel. Eleven of the cases are in the City of Mississauga and 3 cases are in the City of Brampton. Legionellosis is an acute...

Post

Neutrogena Beach Defense and Ultra Sheer aerosol spray sunscreens recalled due to elevated benzene levels

Johnson & Johnson Inc. is recalling all lots of Neutrogena Beach Defense and Ultra Sheer children and adult sunscreens, in aerosol spray format, after testing conducted by the company detected elevated levels of benzene. Frequent and long-term exposure (e.g., through the skin and by inhalation) to elevated levels of benzene may pose serious health risks....

Post

Clarification on WHO statement about COVID-19 vaccine interchangeability

The media has recently reported that a physician associated with the World Health Organization (WHO) suggested that the mixing of vaccines was a ‘dangerous trend’. This was not an official statement by the World Health Organization. The statement was made at a session unrelated to vaccine mixing and was taken out of context by news...

Post

Real World Evidence for COVID-19 Vaccines

Similar to clinical trials, real world cohort and case-control studies find COVID-19 infections are reduced by >90% with two doses of mRNA vaccines. Single doses of either mRNA or AstraZeneca vaccine decreases infections by ~60% and hospitalizations by 70-80%. Vaccine effectiveness appears similar for variants of concern and are safe for pregnant women. HMC

Post

Updated information on AstraZeneca/COVISHIELD COVID-19 vaccines

On June 29, 2021, Health Canada issued a Health Product Risk Communication regarding the AstraZeneca/COVISHIELD COVID-19 vaccine: https://healthycanadians.gc.ca/recall-alert-rappel- avis/hc-sc/2021/75389a-eng.php Health Canada has updated the product monograph for the AstraZeneca and COVISHIELD COVID-19 vaccines to add capillary leak syndrome as a potential side effect following vaccination. Patients with a history of capillary leak syndrome should not...

Post

Second dose of COVID-19 Vaccination

NACI has provided updated recommendations on COVID-19 vaccine schedules. For those who have received a first dose of an AstraZeneca vaccine, an mRNA vaccine is preferred for the second dose due to emerging evidence suggesting better immune response, and, to mitigate the risk of VITT(Vaccine-Induced Thrombotic Thrombocytopenia) from viral vector vaccines. HMC

Post

Myocarditis Risk

Since May 2021, the Public Health Agency of Canada has been actively monitoring reports of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines through passive and active Canadian safety surveillance systems. Available information from international reports, including those from Israel and the United States, indicated that: cases were more commonly reported after the second dose, and...

Post

COVID-19 Second Dose Booking

Residents aged 70 and over, as well as those who received the first dose of an mRNA COVID-19 vaccine on or before April 18, 2021 are now able to book their second dose appointments. The provincial booking system will allow these individuals to book appointments as of Monday, June 7, 2021 at 8:00 am. This...

Post

Second Dose COVID-19 Vaccine Type-Interchangeability, Updated on June3, 2021

NACI recommends that persons who received a first dose of the AstraZeneca/COVISHIELD vaccine may receive either AstraZeneca/COVISHIELD vaccine or an mRNA vaccine (Pfizer-BioNTech or Moderna) for their second dose, unless contraindicated. On June 1, the Public Health Agency of Canada released updated recommendations from the National Advisory Committee on Immunization (NACI) on the interchangeability of authorized...

Post

Receiving the COVID-19 Vaccine after CPVID-19 infection

Peel Public Health has confirmed with the Ministry of Health Emergency Operations centre that individuals with a previous COVID-19 infection may receive their COVID-19 vaccination at any time after they have recovered as long as they have completed self-isolation and have been symptom-free for at least 24 hours. HMC